Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
65.06
Dollar change
+1.50
Percentage change
2.36
%
IndexNDX, S&P 500 P/E181.38 EPS (ttm)0.36 Insider Own0.09% Shs Outstand1.25B Perf Week0.56%
Market Cap81.05B Forward P/E9.06 EPS next Y7.18 Insider Trans-2.22% Shs Float1.24B Perf Month-2.91%
Income484.00M PEG33.68 EPS next Q1.59 Inst Own85.66% Short Float2.04% Perf Quarter-11.71%
Sales27.42B P/S2.96 EPS this Y-43.83% Inst Trans0.85% Short Ratio3.61 Perf Half Y-21.70%
Book/sh14.08 P/B4.62 EPS next Y90.27% ROA0.82% Short Interest25.43M Perf Year-16.54%
Cash/sh4.86 P/C13.38 EPS next 5Y5.38% ROE2.51% 52W Range62.07 - 87.86 Perf YTD-19.69%
Dividend Est.3.10 (4.77%) P/FCF10.26 EPS past 5Y1.55% ROI1.24% 52W High-25.95% Beta0.19
Dividend TTM3.79 (5.83%) Quick Ratio0.94 Sales past 5Y4.16% Gross Margin77.68% 52W Low4.82% ATR (14)1.33
Dividend Ex-DateJun 14, 2024 Current Ratio1.08 EPS Y/Y TTM-91.37% Oper. Margin34.04% RSI (14)48.67 Volatility2.15% 1.97%
Employees18000 Debt/Eq1.44 Sales Y/Y TTM2.13% Profit Margin1.77% Recom2.16 Target Price82.17
Option/ShortYes / Yes LT Debt/Eq1.23 EPS Q/Q-517.48% Payout66.62% Rel Volume1.28 Prev Close63.56
Sales Surprise5.17% EPS Surprise11.60% Sales Q/Q5.66% EarningsApr 25 AMC Avg Volume7.04M Price65.06
SMA20-0.24% SMA50-1.71% SMA200-12.47% Trades Volume9,793,590 Change2.36%
Date Action Analyst Rating Change Price Target Change
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Feb-22-24Downgrade Truist Buy → Hold $91 → $82
Nov-09-23Initiated Deutsche Bank Hold $75
Sep-08-23Upgrade BofA Securities Neutral → Buy $88 → $95
Sep-06-23Initiated HSBC Securities Reduce $71
Jul-24-23Reiterated Barclays Equal Weight $81 → $80
May-16-23Upgrade BMO Capital Markets Market Perform → Outperform $90 → $100
Apr-28-23Resumed Piper Sandler Overweight $105
Jan-03-23Downgrade RBC Capital Mkts Outperform → Sector Perform $87
Jun-14-24 04:19PM
02:27PM
07:01AM
03:00AM
Jun-13-24 06:00PM
09:00AM Loading…
Jun-12-24 09:00AM
Jun-08-24 06:50AM
Jun-07-24 05:50PM
11:36AM
11:35AM
Jun-06-24 09:00AM
04:45AM
04:30AM
Jun-05-24 09:45AM
09:15AM
07:55AM Loading…
07:55AM
07:00AM
06:40AM
05:06AM
04:25AM
02:00AM
Jun-04-24 03:57PM
06:15AM
Jun-03-24 04:26PM
04:17PM
01:59PM
10:00AM
09:00AM
Jun-02-24 08:00AM
Jun-01-24 08:00AM
01:01PM Loading…
May-31-24 01:01PM
12:18PM
08:07AM
07:01AM
04:25AM
May-30-24 04:45PM
May-29-24 02:02PM
06:05AM
May-28-24 09:50AM
09:45AM
May-27-24 12:32PM
May-25-24 11:10PM
May-22-24 05:17PM
10:48AM
08:30AM
May-21-24 10:15AM
09:00AM
May-20-24 11:36AM
10:43AM
May-18-24 08:30AM
08:06AM
May-17-24 08:06AM
May-16-24 02:27PM
May-14-24 10:09AM
08:45AM
May-13-24 12:41PM
May-10-24 09:00AM
May-09-24 04:05PM
04:05PM
09:45AM
06:49AM
01:07AM
May-07-24 09:45AM
08:30AM
May-06-24 12:39PM
May-04-24 07:38AM
May-03-24 08:11PM
02:00PM
May-02-24 11:29AM
May-01-24 02:38PM
10:53AM
10:19AM
08:25AM
Apr-30-24 04:05PM
12:01PM
Apr-29-24 09:00AM
08:18AM
06:01AM
Apr-28-24 05:50PM
Apr-26-24 04:31PM
04:10PM
11:44AM
10:45AM
10:24AM
10:09AM
10:08AM
09:59AM
09:14AM
08:11AM
08:00AM
03:35AM
Apr-25-24 09:45PM
06:00PM
05:49PM
05:41PM
05:15PM
04:59PM
04:50PM
04:40PM
04:14PM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM
Dickinson Andrew DChief Financial OfficerOct 17 '23Sale80.005,000400,017104,003Oct 18 04:31 PM
Parsey MerdadChief Medical OfficerSep 12 '23Sale76.991,501115,56270,130Sep 13 06:50 PM
Dickinson Andrew DChief Financial OfficerJul 20 '23Sale80.005,000400,000107,587Jul 21 05:30 PM
GILEAD SCIENCES, INC.10% OwnerJun 28 '23Buy19.261,010,00019,452,60014,823,029Jun 30 03:12 PM
GILEAD SCIENCES, INC.10% OwnerJun 27 '23Buy3.752,930,87010,990,76216,635,286Jun 28 05:17 PM